Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
AJNR. American Journal of Neuroradiology|July 12, 2024
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with <i>IDH</i>-Mutant GliomaLucia Nichelli, Capucine Cadin, Patrizia Lazzari, et al.
Nature Communications|November 16, 2018
Microfluidic active loading of single cells enables analysis of complex clinical specimensNicholas L Calistri, Robert J Kimmerling, Seth W Malinowski, et al.
Acta Neuropathologica Communications|September 9, 2018
Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcomeRomain Appay, Emeline Tabouret, Mehdi Touat, et al.
Neuro-Oncology Practice|March 9, 2026
Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 casesMehdi Touat, Jacqueline Lehmann-Che, Salah Eddine O Kacimi, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastomaHan Xu, Sungwoon Lee, Felipe Leser, et al.
The Oncologist|January 4, 2021
Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic ChallengesCristina Birzu, Suzanne Tran, Franck Bielle, et al.
Journal of Neuro-Oncology|August 4, 2018
Clinical activity and safety of atezolizumab in patients with recurrent glioblastomaRimas V Lukas, Jordi Rodon, Kevin Becker, et al.
Neuro-Oncology|October 21, 2024
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohortDomique Figarella-Branger, Carole Colin, Karima Mokhtari, et al.
Journal of Neuro-Oncology|May 16, 2015
Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survivalMarcos A dos Santos, Jean-Pierre Pignon, Pierre Blanchard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomasJulia Delahousse, Loic Verlingue, Sophie Broutin, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
AJNR. American Journal of Neuroradiology|July 12, 2024
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with <i>IDH</i>-Mutant GliomaLucia Nichelli, Capucine Cadin, Patrizia Lazzari, et al.
Nature Communications|November 16, 2018
Microfluidic active loading of single cells enables analysis of complex clinical specimensNicholas L Calistri, Robert J Kimmerling, Seth W Malinowski, et al.
Acta Neuropathologica Communications|September 9, 2018
Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcomeRomain Appay, Emeline Tabouret, Mehdi Touat, et al.
Neuro-Oncology Practice|March 9, 2026
Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 casesMehdi Touat, Jacqueline Lehmann-Che, Salah Eddine O Kacimi, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastomaHan Xu, Sungwoon Lee, Felipe Leser, et al.
The Oncologist|January 4, 2021
Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic ChallengesCristina Birzu, Suzanne Tran, Franck Bielle, et al.
Journal of Neuro-Oncology|August 4, 2018
Clinical activity and safety of atezolizumab in patients with recurrent glioblastomaRimas V Lukas, Jordi Rodon, Kevin Becker, et al.
Neuro-Oncology|October 21, 2024
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohortDomique Figarella-Branger, Carole Colin, Karima Mokhtari, et al.
Journal of Neuro-Oncology|May 16, 2015
Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survivalMarcos A dos Santos, Jean-Pierre Pignon, Pierre Blanchard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomasJulia Delahousse, Loic Verlingue, Sophie Broutin, et al.
Pageof 10